Compare Charles River Laboratories Intl. Inc (CRL) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs PubMatic Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while PubMatic Inc trades at $18.64 (market cap $850.88M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 16.7× PubMatic Inc's market cap, and PubMatic Inc is more actively traded (997,698 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and PubMatic Inc for 40 Days on average.
| CRL | PUBM | |
|---|---|---|
Market Cap | $14.23B | $850.88M |
Volume | 1,176,885 | 997,698 |
Sector | Health | Technology |
52-Week High | $310.77 | $19.18 |
52-Week Low | $149.93 | $6.28 |
Typical Hold Time | 33 Days | 40 Days |
Enterprise Value | $17.06B | $754.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
PubMatic (PUBM) trades at $18.64, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock has beaten earnings estimates for the last three quarters, though it remains unprofitable with a negative net income margin. Recent news highlights strong Q2 2026 results, AI product adoption, and executive appointments, fueling positive sentiment.
The outlook is cautiously optimistic given analyst consensus and technical momentum, but risks include persistent profitability challenges and competitive pressures. Upside is supported by a $19.89 average price target, though investors should weigh high valuation multiples against earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
